CommentaryPolicy

Reengineering Translational Science: The Time Is Right

See allHide authors and affiliations

Science Translational Medicine  06 Jul 2011:
Vol. 3, Issue 90, pp. 90cm17
DOI: 10.1126/scitranslmed.3002747

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • Reengineering Translational Science: Is the NIH the right place for this?
    • Sean Ekins, Senior Consultant
    • Other Contributors:

    We read with interest Dr. Collins’ Commentary on “Reengineering Translational Science: The time is Right.” We agree that there is an urgent need to revamp the way that drugs are developed, to bring therapeutics to market faster, and to provide incentives to generate treatments for neglected and rare diseases. We question, however, whether the NIH as it stands can adequately pursue these goals when an entire industry is struggl...

    Show More
    Competing Interests: None declared.

Navigate This Article